CRISPR Therapeutics (CRSP) Short Interest Ratio & Short Volume → Truth about Trump you’ve never heard (From Porter & Company) (Ad) Free CRSP Stock Alerts $52.99 -1.84 (-3.36%) (As of 04/30/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media CRISPR Therapeutics Short Interest DataCurrent Short Volume14,740,000 sharesPrevious Short Volume14,760,000 sharesChange Vs. Previous Month-0.14%Dollar Volume Sold Short$865.53 millionShort Interest Ratio / Days to Cover8.5Last Record DateApril 15, 2024Outstanding Shares84,880,000 sharesPercentage of Shares Shorted17.37%Today's Trading Volume1,116,732 sharesAverage Trading Volume1,790,041 sharesToday's Volume Vs. Average62% Short Selling CRISPR Therapeutics ? Sign up to receive the latest short interest report for CRISPR Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCRSP Short Interest Over TimeCRSP Days to Cover Over TimeCRSP Percentage of Float Shorted Over Time Ad Porter & CompanyTrump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. For the full story, click here. CRISPR Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202414,740,000 shares $865.53 million -0.1%N/A8.5 $58.72 3/31/202414,760,000 shares $1.01 billion +0.3%N/A7.9 $68.16 3/15/202414,720,000 shares $1.07 billion -2.3%N/A7.4 $72.95 2/29/202415,060,000 shares $1.27 billion +1.3%N/A5.8 $84.22 2/15/202414,870,000 shares $1.26 billion -5.5%N/A5.5 $84.48 1/31/202415,740,000 shares $990.83 million -7.6%N/A5.6 $62.95 Get the Latest News and Ratings for CRSP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/202417,040,000 shares $1.09 billion +4.9%N/A5.8 $64.25 12/31/202316,250,000 shares $1.02 billion -6.2%N/A5.9 $62.60 12/15/202317,330,000 shares $1.08 billion +8.8%N/A6.6 $62.08 11/30/202315,930,000 shares $1.06 billion -2.7%N/A7 $66.73 11/15/202316,370,000 shares $920.49 million +17.9%N/A9.6 $56.23 10/31/202313,890,000 shares $540.74 million +2.5%N/A10.9 $38.93 10/15/202313,550,000 shares $600.40 million +3.9%N/A13.3 $44.31 9/30/202313,040,000 shares $591.89 million -5.4%N/A13.4 $45.39 9/15/202313,790,000 shares $697.50 million -2.1%N/A14.6 $50.58 8/31/202314,080,000 shares $704.14 million +5.0%N/A13.7 $50.01 8/15/202313,410,000 shares $652.80 million +10.7%N/A11.9 $48.68 7/31/202312,110,000 shares $694.27 million -1.6%N/A9.5 $57.33 7/15/202312,310,000 shares $700.56 million -2.1%N/A9.8 $56.91 6/30/202312,570,000 shares $705.68 million +0.8%16.6%9.2 $56.14 6/15/202312,470,000 shares $734.98 million +2.3%16.5%9 $58.94 5/31/202312,190,000 shares $780.65 million -1.9%16.1%9.1 $64.04 5/15/202312,430,000 shares $819.76 million -5.8%16.4%9.5 $65.95 4/30/202313,200,000 shares $646.01 million +1.9%17.5%11.1 $48.94 4/15/202312,950,000 shares $651.51 million +2.0%17.2%11.3 $50.31 3/31/202312,700,000 shares $574.42 million +4.3%16.9%12.2 $45.23 3/15/202312,180,000 shares $547.13 million +9.0%16.2%11.3 $44.92 2/28/202311,170,000 shares $550.90 million +9.0%14.8%10 $49.32 2/15/202310,250,000 shares $534.74 million +2.7%13.7%9.4 $52.17 1/31/20239,980,000 shares $509.18 million +1.0%13.3%9.2 $51.02 1/15/20239,880,000 shares $493.41 million -5.7%13.2%9.1 $49.94 12/30/202210,480,000 shares $426.01 million +12.2%14.0%9.9 $40.65 12/15/20229,340,000 shares $443.65 million -16.2%12.4%8.8 $47.50 11/30/202211,140,000 shares $610.36 million -4.3%14.8%10.6 $54.79 11/15/202211,640,000 shares $710.16 million -7.3%15.5%10.8 $61.01 10/31/202212,550,000 shares $656.87 million +6.7%16.7%11.4 $52.34 10/15/202211,760,000 shares $635.86 million +1.7%15.7%10.4 $54.07 9/30/202211,560,000 shares $755.45 million +5.8%16.1%9.1 $65.35 9/15/202210,930,000 shares $819.86 million +0.5%15.3%7.5 $75.01 8/31/202210,880,000 shares $708.18 million +1.5%15.2%6 $65.09Trump’s last act as President (Ad)You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. For the full story, click here. CRSP Short Interest - Frequently Asked Questions What is CRISPR Therapeutics' current short interest? Short interest is the volume of CRISPR Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 14,740,000 shares of CRSP short. Learn More on CRISPR Therapeutics' current short interest. What is a good short interest ratio for CRISPR Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CRSP shares currently have a short interest ratio of 8.0. Learn More on CRISPR Therapeutics's short interest ratio. Which institutional investors are shorting CRISPR Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of CRISPR Therapeutics: Simplex Trading LLC, IMC Chicago LLC, IMC Chicago LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is CRISPR Therapeutics' short interest increasing or decreasing? CRISPR Therapeutics saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 14,740,000 shares, a decline of 0.1% from the previous total of 14,760,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does CRISPR Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to CRISPR Therapeutics: Halozyme Therapeutics, Inc. (6.55%), Krystal Biotech, Inc. (8.59%), Immunovant, Inc. (14.08%), ImmunityBio, Inc. (40.05%), Revolution Medicines, Inc. (7.33%), Iovance Biotherapeutics, Inc. (22.19%), SpringWorks Therapeutics, Inc. (14.28%), Vaxcyte, Inc. (7.58%), Apogee Therapeutics, Inc. (12.97%), Arcellx, Inc. (10.13%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short CRISPR Therapeutics stock? Short selling CRSP is an investing strategy that aims to generate trading profit from CRISPR Therapeutics as its price is falling. CRSP shares are trading down $1.45 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against CRISPR Therapeutics? A short squeeze for CRISPR Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CRSP, which in turn drives the price of the stock up even further. How often is CRISPR Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CRSP, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Halozyme Therapeutics Short Interest Krystal Biotech Short Interest Immunovant Short Interest ImmunityBio Short Interest Revolution Medicines Short Interest Iovance Biotherapeutics Short Interest SpringWorks Therapeutics Short Interest Vaxcyte Short Interest Apogee Therapeutics Short Interest Arcellx Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CRSP) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersThe Gold Grab of the CenturyColonial MetalsProtect Your Bank Account Before It’s Too LateWeiss RatingsTrump’s last act as President Porter & CompanyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsIs Tesla going out of business?DTIThe A.I. story nobody is telling you (Read ASAP)TradeSmithElon Musk Secret Crypto Plot ExposedCrypto 101 MediaHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace